Table 2. Indications and monitoring items for anticoagulant drug monitoring.

Anticoagulant drugs	Monitoring indicators	Monitoring items
UFH	Routine monitoring	aPTT or anti-Xa (aPTT exceeds the upper limit of normal or is >1.5 times the patient’s baseline value)
LMWH	Severe renal impairment, cancer patients with venous thrombosis, bleeding	Anti-Xa
DOACs	Bleeding, PARPi treatment	Anti-Xa

Anti-Xa, anti-factor Xa; aPTT, activated partial thromboplastin time; DOACs, direct oral anticoagulants; LMWH, low-molecular- weight heparin; UFH, unfractionated heparin.